Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed
Executive Summary
The first regulatory application for a point-of-care assay for genotyping patients for response to antiplatelet therapy was submitted at the end of August - if Nanosphere's test is approved, it could make genotyping a more feasible routine tool for guiding therapy for Plavix
You may also be interested in...
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
FDA's three-month postponement of a decision on AstraZeneca PLC’s NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.